Evolvable signaling networks of receptor tyrosine kinases: relevance of robustness to malignancy and to cancer therapy
暂无分享,去创建一个
[1] M. Freeman. Feedback control of intercellular signalling in development , 2000, Nature.
[2] L. Lau,et al. Expression of a set of growth-related immediate early genes in BALB/c 3T3 cells: coordinate regulation with c-fos or c-myc. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[3] J. Ptak,et al. High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.
[4] H. Kitano. Cancer as a robust system: implications for anticancer therapy , 2004, Nature Reviews Cancer.
[5] Ivan Dikic,et al. Negative receptor signalling. , 2003, Current opinion in cell biology.
[6] Doyle,et al. Highly optimized tolerance: robustness and design in complex systems , 2000, Physical review letters.
[7] R. Stein,et al. Evolutionary Analysis of the ErbB Receptor and Ligand Families , 2000, Journal of Molecular Evolution.
[8] P. N. Rao,et al. Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.
[9] Michael Tsang,et al. Promotion and Attenuation of FGF Signaling Through the Ras-MAPK Pathway , 2004, Science's STKE.
[10] Wendy S. Beane,et al. The sea urchin kinome: a first look. , 2006, Developmental biology.
[11] R. Nahta,et al. HER2 therapy: Molecular mechanisms of trastuzumab resistance , 2006, Breast Cancer Research.
[12] M. Mann,et al. Phosphotyrosine interactome of the ErbB-receptor kinase family , 2005, Molecular systems biology.
[13] Y. Yarden,et al. Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases , 2004, Oncogene.
[14] Jae-Hoon Kim,et al. Crystal Structure of the Complex of Human Epidermal Growth Factor and Receptor Extracellular Domains , 2002, Cell.
[15] D. Hanahan,et al. The Hallmarks of Cancer , 2000, Cell.
[16] H. Kitano,et al. A comprehensive pathway map of epidermal growth factor receptor signaling , 2005, Molecular systems biology.
[17] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[18] A. Smith,et al. The complex of polyoma virus middle‐T antigen and pp60c‐src. , 1984, The EMBO journal.
[19] Ralf J. Sommer,et al. The evolution of signalling pathways in animal development , 2003, Nature Reviews Genetics.
[20] Y. Yarden,et al. Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.
[21] Wen-Hsiung Li,et al. Origins, lineage-specific expansions, and multiple losses of tyrosine kinases in eukaryotes. , 2004, Molecular biology and evolution.
[22] Edouard C. Nice,et al. Crystal Structure of a Truncated Epidermal Growth Factor Receptor Extracellular Domain Bound to Transforming Growth Factor α , 2002, Cell.
[23] Andrey Rzhetsky,et al. Birth of scale-free molecular networks and the number of distinct DNA and protein domains per genome , 2001, Bioinform..
[24] I. Verma,et al. Regulation of proto-oncogene fos: a paradigm for early response genes. , 1988, Cold Spring Harbor symposia on quantitative biology.
[25] John Kuriyan,et al. An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor Receptor , 2006, Cell.
[26] A. Barabasi,et al. Network biology: understanding the cell's functional organization , 2004, Nature Reviews Genetics.
[27] P. Carmeliet,et al. Angiogenesis in cancer and other diseases , 2000, Nature.
[28] Gavin MacBeath,et al. A quantitative protein interaction network for the ErbB receptors using protein microarrays , 2006, Nature.
[29] L. Alberghina,et al. Molecular evolution of the neurotrophin family members and their Trk receptors. , 2007, Gene.
[30] S. Hirota,et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.
[31] Carine Maenhaut,et al. Gene expression in human thyrocytes and autonomous adenomas reveals suppression of negative feedbacks in tumorigenesis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[32] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[33] L. Cantley,et al. Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[34] T. Miyata,et al. Divergence pattern of animal gene families and relationship with the Cambrian explosion , 2001, BioEssays : news and reviews in molecular, cellular and developmental biology.
[35] Muffy Calder,et al. When kinases meet mathematics: the systems biology of MAPK signalling , 2005, FEBS letters.
[36] J. Doyle,et al. Bow Ties, Metabolism and Disease , 2022 .
[37] P. Blackshear,et al. Feedback Inhibition of Macrophage Tumor Necrosis Factor-α Production by Tristetraprolin , 1998 .
[38] H. Varmus,et al. Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain , 2005, PLoS medicine.
[39] A. Sharrocks,et al. Id helix–loop–helix proteins inhibit nucleoprotein complex formation by the TCF ETS‐domain transcription factors , 1999, The EMBO journal.
[40] Y. Yarden,et al. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[41] R. Solé,et al. Evolving protein interaction networks through gene duplication. , 2003, Journal of theoretical biology.
[42] Shuang Huang,et al. Involvement of MicroRNA in AU-Rich Element-Mediated mRNA Instability , 2005, Cell.
[43] G. Barton,et al. Emerging roles of pseudokinases. , 2006, Trends in cell biology.
[44] P. Hegde,et al. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[45] M. Levine,et al. A genomewide survey of developmentally relevant genes in Ciona intestinalis , 2003, Development Genes and Evolution.
[46] al. et,et al. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B , 1995, Science.
[47] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[48] L. Presta,et al. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets , 2000, Nature Medicine.
[49] Eytan Domany,et al. A module of negative feedback regulators defines growth factor signaling , 2007, Nature Genetics.
[50] B. Kholodenko. Cell-signalling dynamics in time and space , 2006, Nature Reviews Molecular Cell Biology.
[51] R. Milo,et al. Network motifs in integrated cellular networks of transcription-regulation and protein-protein interaction. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[52] T. Hunter,et al. Signaling—2000 and Beyond , 2000, Cell.
[53] Napoleone Ferrara,et al. VEGF as a Therapeutic Target in Cancer , 2005, Oncology.
[54] N. Satoh,et al. A genomewide survey of developmentally relevant genes in Ciona intestinalis , 2003, Development Genes and Evolution.
[55] C. Tacchetti,et al. TGFalpha expression impairs Trastuzumab-induced HER2 downregulation. , 2005, Oncogene.
[56] James E. Ferrell,et al. A positive-feedback-based bistable ‘memory module’ that governs a cell fate decision , 2007, Nature.
[57] J. Ferrell,et al. A positive-feedback-based bistable ‘memory module’ that governs a cell fate decision , 2003, Nature.
[58] S. Hubbard,et al. Protein tyrosine kinase structure and function. , 2000, Annual review of biochemistry.
[59] Ming Tan,et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. , 2004, Cancer cell.
[60] R. Götz,et al. BuCy RAFs drive cells into MEK addiction. , 2006, Cancer cell.
[61] M. Borrello,et al. The multiple endocrine neoplasia type 2B point mutation switches the specificity of the Ret tyrosine kinase towards cellular substrates that are susceptible to interact with Crk and Nck , 1997, Oncogene.
[62] Karen E. Pilcher,et al. The Dictyostelium Kinome—Analysis of the Protein Kinases from a Simple Model Organism , 2006, PLoS genetics.
[63] C. Sawyers,et al. Treating Imatinib-Resistant Leukemia: The Next Generation Targeted Therapies , 2006, TheScientificWorldJournal.
[64] F. Bruggeman,et al. Cancer: a Systems Biology disease. , 2006, Bio Systems.
[65] A. Ullrich,et al. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences , 1984, Nature.
[66] M. Freeman,et al. Control of EGF Receptor Signalling: Lessons from Fruitflies , 2004, Cancer and Metastasis Reviews.
[67] M. Lynch,et al. The evolutionary fate and consequences of duplicate genes. , 2000, Science.
[68] Hiroaki Kitano,et al. Biological robustness , 2008, Nature Reviews Genetics.
[69] T. Hunter,et al. Oncogenic kinase signalling , 2001, Nature.
[70] U. Alon. Biological Networks: The Tinkerer as an Engineer , 2003, Science.
[71] Carlos L Arteaga,et al. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. , 2006, Cancer cell.
[72] Susan Lindquist,et al. Under cover: causes, effects and implications of Hsp90‐mediated genetic capacitance , 2004, BioEssays : news and reviews in molecular, cellular and developmental biology.
[73] J. Baselga,et al. Targeting Tyrosine Kinases in Cancer: The Second Wave , 2006, Science.
[74] D. Tautz. Evolution of transcriptional regulation. , 2000, Current opinion in genetics & development.
[75] Christopher U. Jones,et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. , 2006, The New England journal of medicine.
[76] P. Blackshear,et al. Feedback inhibition of macrophage tumor necrosis factor-alpha production by tristetraprolin. , 1998, Science.
[77] H. Lane,et al. ERBB Receptors and Cancer: The Complexity of Targeted Inhibitors , 2005, Nature Reviews Cancer.
[78] Paul W. Sternberg,et al. The let-23 gene necessary for Caenorhabditis elegans vulval induction encodes a tyrosine kinase of the EGF receptor subfamily , 1990, Nature.
[79] K. Kinzler,et al. Cancer genes and the pathways they control , 2004, Nature Medicine.
[80] P. Bastiaens,et al. Growth factor-induced MAPK network topology shapes Erk response determining PC-12 cell fate , 2007, Nature Cell Biology.
[81] D. Birnbaum,et al. Phylogenetic Analysis of Ciona intestinalis Gene Superfamilies Supports the Hypothesis of Successive Gene Expansions , 2004, Journal of Molecular Evolution.
[82] D. Morrison,et al. Protein Kinases and Phosphatases in the Drosophila Genome , 2000, The Journal of cell biology.
[83] I. Weinstein. Addiction to Oncogenes--the Achilles Heal of Cancer , 2002, Science.
[84] A. Ullrich,et al. Multiple G-protein-coupled receptor signals converge on the epidermal growth factor receptor to promote migration and invasion , 2004, Oncogene.
[85] D. A. Baxter,et al. Mathematical Modeling of Gene Networks , 2000, Neuron.
[86] J. L. Bos,et al. ras oncogenes in human cancer: a review. , 1989, Cancer research.
[87] Stuart K. Kim,et al. Signaling specificity: the RTK/RAS/MAP kinase pathway in metazoans. , 1999, Trends in genetics : TIG.
[88] Rüdiger Klein,et al. Mig6 is a negative regulator of EGF receptor–mediated skin morphogenesis and tumor formation , 2006, Nature Medicine.
[89] Annie Z. Tremp. Malaria: Plasmodium develops in lymph nodes , 2006, Nature Reviews Microbiology.
[90] C. Vieira,et al. Is genome size influenced by colonization of new environments in dipteran species? , 2005, Molecular ecology.
[91] Albert,et al. Emergence of scaling in random networks , 1999, Science.
[92] J. Isola,et al. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. , 2005, Cancer research.
[93] J. Stelling,et al. Robustness of Cellular Functions , 2004, Cell.
[94] Yosef Yarden,et al. Cancer therapeutic antibodies come of age: Targeting minimal residual disease , 2007, Molecular oncology.
[95] Y. Yarden,et al. Pathogenic poxviruses reveal viral strategies to exploit the ErbB signaling network , 1998, The EMBO journal.
[96] D. Lauffenburger,et al. Time-resolved Mass Spectrometry of Tyrosine Phosphorylation Sites in the Epidermal Growth Factor Receptor Signaling Network Reveals Dynamic Modules*S , 2005, Molecular & Cellular Proteomics.
[97] Somasekar Seshagiri,et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-κB signalling , 2004, Nature.